ADNI is currently accepting Letters of Intent to submit proposals concerning biomarkers or other assessment tools Read more
Welcome
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) unites researchers with study data as they work to define the progression of Alzheimer’s disease (AD). ADNI researchers collect, validate and utilize data, including MRI and PET images, genetics, cognitive tests, CSF and blood biomarkers as predictors of the disease. Study resources and data from the North American ADNI study are available through this website, including Alzheimer’s disease patients, mild cognitive impairment subjects, and elderly controls.
Click below to learn more or to join the ADNI study as a participant.
Returning users
Welcome to the new website with added content for ADNI3. The site builds upon the ADNI1, ADNI-GO, and ADNI2 studies, public-private collaborations aimed at determining the relationships between clinical, cognitive, imaging, genetic, and biochemical biomarkers across the entire spectrum of Alzheimer’s disease. ADNI3 will continue efforts to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD clinical research.
Please comment on the website here.
